1976 related articles for article (PubMed ID: 2952219)
1. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
Weick BG; Walters JR
Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
[TBL] [Abstract][Full Text] [Related]
2. Role of the substantia nigra in the expression of dopamine D1 receptor-mediated and D2 receptor-mediated behaviours.
Fletcher GH; Starr MS
Neuroscience; 1987 Dec; 23(3):1001-10. PubMed ID: 2963970
[TBL] [Abstract][Full Text] [Related]
3. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
4. Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.
LaHoste GJ; Marshall JF
Behav Brain Res; 1990 May; 38(3):233-42. PubMed ID: 1973041
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
Huang KX; Walters JR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of D1 and D2 dopamine receptor agonists on substantia nigra pars reticulata neurons.
Waszczak BL
Brain Res; 1990 Apr; 513(1):125-35. PubMed ID: 2140951
[TBL] [Abstract][Full Text] [Related]
7. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
Engber TM; Anderson JJ; Boldry RC; Kuo S; Chase TN
Neuroscience; 1993 Jun; 54(4):1051-61. PubMed ID: 8101981
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
Engber TM; Marin C; Susel Z; Chase TN
Eur J Pharmacol; 1993 Jun; 236(3):385-93. PubMed ID: 8102970
[TBL] [Abstract][Full Text] [Related]
9. Nigrostriatal lesion alters neurophysiological responses to selective and nonselective D-1 and D-2 dopamine agonists in rat globus pallidus.
Carlson JH; Bergstrom DA; Demo SD; Walters JR
Synapse; 1990; 5(2):83-93. PubMed ID: 2309160
[TBL] [Abstract][Full Text] [Related]
10. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
Wachtel SR; Hu XT; Galloway MP; White FJ
Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
[TBL] [Abstract][Full Text] [Related]
11. Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions.
Trugman JM; Wooten GF
J Neurosci; 1987 Sep; 7(9):2927-35. PubMed ID: 3114439
[TBL] [Abstract][Full Text] [Related]
12. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.
Hu XT; Wachtel SR; Galloway MP; White FJ
J Neurosci; 1990 Jul; 10(7):2318-29. PubMed ID: 1973947
[TBL] [Abstract][Full Text] [Related]
13. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes.
Jiang HK; McGinty JF; Hong JS
Brain Res; 1990 Jan; 507(1):57-64. PubMed ID: 1967976
[TBL] [Abstract][Full Text] [Related]
14. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Sonsalla PK; Manzino L; Heikkila RE
J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
[TBL] [Abstract][Full Text] [Related]
15. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
16. Neurophysiological investigation of effects of the D-1 agonist SKF 38393 on tonic activity of substantia nigra dopamine neurons.
Carlson JH; Bergstrom DA; Weick BG; Walters JR
Synapse; 1987; 1(5):411-6. PubMed ID: 2975067
[TBL] [Abstract][Full Text] [Related]
17. Substantia nigra D1 receptors and stimulation of striatal cholinergic interneurons by dopamine: a proposed circuit mechanism.
Abercrombie ED; DeBoer P
J Neurosci; 1997 Nov; 17(21):8498-505. PubMed ID: 9334422
[TBL] [Abstract][Full Text] [Related]
18. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
Pollack AE; Yates TM
Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
[TBL] [Abstract][Full Text] [Related]
19. SKF 38393 alters the rate-dependent D2-mediated inhibition of nigrostriatal but not mesoaccumbens dopamine neurons.
Kelland MD; Freeman AS; Chiodo LA
Synapse; 1988; 2(4):416-23. PubMed ID: 2973142
[TBL] [Abstract][Full Text] [Related]
20. Effects of individual and concurrent stimulation of striatal D1 and D2 dopamine receptors on electrophysiological and behavioral output from rat basal ganglia.
Waszczak BL; Martin LP; Finlay HE; Zahr N; Stellar JR
J Pharmacol Exp Ther; 2002 Mar; 300(3):850-61. PubMed ID: 11861790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
